Michael Li, MD, MPH

Assistant Clinical Professor

Dr. Michael Li is a transplant hepatologist and gastroenterologist who specializes in caring for patients with cirrhosis, autoimmune liver disease, and liver cancer.

Dr. Li’s research focuses on the relationship between the immune system and liver disease. This includes autoimmune diseases like primary sclerosing cholangitis as well as the use of immunotherapy to treat liver cancer. He seeks to perform meaningful clinical and translational research to achieve a better understanding of immune-mediated liver diseases.

Dr. Li earned his medical degree at the Icahn School of Medicine at Mount Sinai and completed a residency in internal medicine at the Mount Sinai Hospital. He completed a fellowship in gastroenterology at Brigham and Women's Hospital, during which he also earned his MPH degree from the Harvard TH Chan School of Public Health. He then completed a fellowship in transplant hepatology at UCSF before becoming a faculty member in the UCSF Division of Gastroenterology and Hepatology.

Education
Fellowship, 2022 - Transplant Hepatology, UCSF
Fellowship, 2021 - Gastroenterology, Brigham and Women's Hospital
MPH, 2021 - Clinical Effectiveness, Harvard TH Chan School of Public Health
Residency, 2018 - Internal Medicine, The Mount Sinai Hospital
MD, 2015 - , Icahn School of Medicine at Mount Sinai
BS, 2010 - Biology, Brown University
Honors and Awards
  • Pilot Research Award, American Gastroenterological Association, 2023
  • Pilot/Feasibility Award, UCSF Liver Center, 2023
  • Clinical Research Pilot Study Award, American College of Gastroenterology, 2021
  • AASLD Foundation Fellow Abstract Award, Digestive Disease Week, 2021
  • Best of the Liver Meeting, Basic and Translational Research, AASLD, 2020
  • Honors in Research, Mount Sinai Internal Medicine, 2018
  • Presidential Poster of Distinction, AASLD, 2014
  • Howard Hughes Medical Research Fellowship, Howard Hughes Medical Institute, 2013-2014
  • Mount Sinai Research Scholars Program, Icahn School of Medicine at Mount Sinai, 2011
  • Undergraduate Teaching and Research Award, Brown University, 2008
  • Summer Medical and Research Training Program Fellowship, Baylor College of Medicine, 2007
Publications
  1. Shifman HP, Hatchett J, Pai RA, Safer R, Gomel R, Vyas M, Li M, Lai JC, Wadhwani SI. Caregiver-reported symptom burden and preferences for therapeutic goals in pediatric primary sclerosing cholangitis. Journal of pediatric gastroenterology and nutrition 2024. PMID: 38899591


  2. Li M, Bhoori S, Mehta N, Mazzaferro V. Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation. Journal of hepatology 2024. PMID: 38848767


  3. Li M, Pai RA, Gomel R, Vyas M, Callif SC, Hatchett J, Bowlus CL, Lai JC. Patient-focused drug development in primary sclerosing cholangitis: Insights on patient priorities and involvement in clinical trials. Hepatology communications 2024. PMID: 38727680


  4. Li M, Wong D, Sack JS, Vogel AS, Hodi FS, Fong L, Lai JC, Zucker SD, Grover S. Outcomes of high-grade immune checkpoint inhibitor hepatitis in hospitalized and non-hospitalized patients. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2024. PMID: 38401693


  5. Li M, Wong D, Sack JS, Vogel AS, Hodi FS, Fong L, Lai JC, Grover S, Zucker SD. Early Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor-Induced Hepatitis. Journal of the National Comprehensive Cancer Network : JNCCN 2023. PMID: 37308118


  6. Zahir A, Li M, Gill RM, Brandman D. Diagnosis and Management of Drug-Induced Liver Injury After the Use of Polygonum multiflorum. ACG case reports journal 2022. PMID: 36247379


  7. Li M, Wong D, Vogel AS, Sack JS, Rahma OE, Hodi FS, Zucker SD, Grover S. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. Hepatology (Baltimore, Md.) 2021. PMID: 34709662


  8. Li M, Sack JS, Bell P, Rahma OE, Srivastava A, Grover S, Zucker SD. Utility of Liver Biopsy in Diagnosis and Management of High-grade Immune Checkpoint Inhibitor Hepatitis in Patients With Cancer. JAMA oncology 2021. PMID: 34554206


  9. Sack JS, Li M, Zucker SD. Bleeding Outcomes Following Transesophageal Echocardiography in Patients With Cirrhosis and Esophageal Varices. Hepatology communications 2020. PMID: 33553975


  10. Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, Perumalswami P, Roytman M, Li M, Vogel AS, Catana AM, Wegermann K, Carr RM, Aloman C, Chen VL, Rabiee A, Sadowski B, Nguyen V, Dunn W, Chavin KD, Zhou K, Lizaola-Mayo B, Moghe A, Debes J, Lee TH, Branch AD, Viveiros K, Chan W, Chascsa DM, Kwo P, Dhanasekaran R. Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2020. PMID: 32950749


  11. Li M, Chan WW, Zucker SD. Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV. Journal of the American Heart Association 2020. PMID: 32930032


  12. Li M, Sack JS, Rahma OE, Hodi FS, Zucker SD, Grover S. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer 2020. PMID: 32888341


  13. Wood JG, Schwer B, Wickremesinghe PC, Hartnett DA, Burhenn L, Garcia M, Li M, Verdin E, Helfand SL. Sirt4 is a mitochondrial regulator of metabolism and lifespan in Drosophila melanogaster. Proceedings of the National Academy of Sciences of the United States of America 2018. PMID: 29378963


  14. Li M, Pathak RR, Lopez-Rivera E, Friedman SL, Aguirre-Ghiso JA, Sikora AG. The In Ovo Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma. Journal of visualized experiments : JoVE 2015. PMID: 26484588